Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 192

Similar articles for PubMed (Select 21751166)

1.

The influence of non-radioactive iodine (127I) on the outcome of radioiodine (131I) therapy in patients with Graves' disease and toxic nodular goitre.

Rogowski F, Abdelrazek S, Szumowski P, Zonenberg A, Parfienczyk A, Sawicka A.

Nucl Med Rev Cent East Eur. 2011;14(1):9-15.

2.

Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.

Berg GE, Michanek AM, Holmberg EC, Fink M.

J Nucl Med. 1996 Feb;37(2):228-32.

3.

Antithyroid drugs as a factor influencing the outcome of radioiodine therapy in Graves' disease and toxic nodular goitre?

Körber C, Schneider P, Körber-Hafner N, Hänscheid H, Reiners C.

Eur J Nucl Med. 2001 Sep;28(9):1360-4.

PMID:
11585295
4.

Administration of additional inactive iodide during radioiodine therapy for Graves' disease: who might benefit?

Dietlein M, Moka D, Reinholz U, Schmidt M, Schomäcker K, Schicha H, Wellner U.

Nuklearmedizin. 2007;46(3):77-84.

PMID:
17549318
5.

Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.

Franklyn JA, Daykin J, Holder R, Sheppard MC.

QJM. 1995 Mar;88(3):175-80.

PMID:
7767667
6.

Long-term follow-up study of radioiodine treatment of hyperthyroidism.

Metso S, Jaatinen P, Huhtala H, Luukkaala T, Oksala H, Salmi J.

Clin Endocrinol (Oxf). 2004 Nov;61(5):641-8.

PMID:
15521969
7.
8.

Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone.

Nieuwlaat WA, Hermus AR, Ross HA, Buijs WC, Edelbroek MA, Bus JW, Corstens FH, Huysmans DA.

J Nucl Med. 2004 Apr;45(4):626-33.

9.

[Determination of factors affecting the therapeutic outcome of radioiodine therapy in patients with Graves' disease].

Sabri O, Schulz G, Zimny M, Schreckenberger M, Zimny D, Wagenknecht G, Kaiser HJ, Dohmen BM, Bares R, Büll U.

Nuklearmedizin. 1998 May;37(3):83-9. German.

PMID:
9604227
10.

[Effect of iodine application during radioiodine therapy in patients with impending therapy failure].

Urbannek V, Schmidt M, Moka D, Hillger HW, Voth E, Wellner U, Schicha H.

Nuklearmedizin. 2000;39(4):108-12. German.

PMID:
10919161
11.

Radioiodine treatment of hyperthyroidism in patients with low thyroid uptake.

Ruchała M, Sowiński J, Dolata M, Junik R, Gembicki M, Skiba A.

Nucl Med Rev Cent East Eur. 2005;8(1):28-32.

PMID:
15977144
12.

[Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].

Giovanella L, De Palma D, Ceriani L, Vanoli P, Garancini S, Tordiglione M, Tarolo GL.

Radiol Med. 2000 Dec;100(6):480-3. Italian.

PMID:
11307510
13.

Radioiodine treatment of hyperthyroidism: prognostic factors affecting outcome.

Erem C, Kandemir N, Hacihasanoglu A, Ersöz HO, Ukinc K, Kocak M.

Endocrine. 2004 Oct;25(1):55-60.

PMID:
15545707
14.

Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres.

Silva MN, Rubió IG, Romão R, Gebrin EM, Buchpiguel C, Tomimori E, Camargo R, Cardia MS, Medeiros-Neto G.

Clin Endocrinol (Oxf). 2004 Mar;60(3):300-8.

PMID:
15008994
15.

Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I?

Kobe C, Eschner W, Wild M, Rahlff I, Sudbrock F, Schmidt M, Dietlein M, Schicha H.

Nucl Med Commun. 2010 Mar;31(3):201-5. doi: 10.1097/MNM.0b013e328333d303.

PMID:
19907353
16.

Different strategies to overcome the effect of carbimazole on high- and low-dose radioiodine therapy: results from continuous dose-effect models.

Walter MA, Schindler C, Christ-Crain M, Müller-Brand J, Müller B.

Eur J Clin Invest. 2009 Jan;39(1):51-7. doi: 10.1111/j.1365-2362.2008.02061.x.

PMID:
19087129
17.

Optimized radioiodine therapy of Graves' disease: analysis of the delivered dose and of other possible factors affecting outcome.

Catargi B, Leprat F, Guyot M, Valli N, Ducassou D, Tabarin A.

Eur J Endocrinol. 1999 Aug;141(2):117-21.

18.

Radioactive iodine therapy in Graves' hyperthyroidism: a prospective study from a tertiary referral centre in north India.

Sankar R, Sekhri T, Sripathy G, Walia RP, Jain SK.

J Assoc Physicians India. 2005 Jul;53:603-6.

PMID:
16190128
19.

Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome.

Reinhardt MJ, Brink I, Joe AY, Von Mallek D, Ezziddin S, Palmedo H, Krause TM.

Eur J Nucl Med Mol Imaging. 2002 Sep;29(9):1118-24. Epub 2002 Jun 26.

PMID:
12192554
20.

Comparison of different thyroid committed doses in radioiodine therapy for Graves' hyperthyroidism.

Grosso M, Traino A, Boni G, Banti E, Della Porta M, Manca G, Volterrani D, Chiacchio S, AlSharif A, Borsò E, Raschillà R, Di Martino F, Mariani G.

Cancer Biother Radiopharm. 2005 Apr;20(2):218-23.

PMID:
15869459
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk